Aurion Biotech names Holland as chief medical advisor
“Dr. Holland has been an innovator in corneal surgery for his entire career, which is why he recognized very early on that corneal endothelial cell therapy is a game-changer. He has been one of Aurion Biotech’s strongest supporters and we are honored that he’ll deepen his engagement with us,” Greg Kunst, chief executive officer of Aurion Biotech, said in a press release.
As chief medical advisor of Aurion Biotech, Holland will assist in preparing the company’s lead candidate for the treatment of corneal endothelial dysfunction, a cell therapy process that cultures healthy cells from a single donor cornea that can be used in more than 100 recipient eyes.
The therapy was invented by Shigeru Kinoshita, MD, PhD, and his colleagues at Kyoto Prefecture University of Medicine in Japan.
“I’m at a fortunate stage in my career, where I can focus my time and efforts on the projects that matter most to me,” Holland said in the press release. “The team at Aurion Biotech is deeply talented, and I’m delighted to continue the incredible work of Professor Kinoshita and his colleagues at KPUM, for the benefit of millions of patients who suffer from corneal endothelial disease.”
Collapse
Read more about